

1 **Understanding Symptom Profiles of Depression with the PHQ-9 in a Community Sample**  
2 **Using Network Analysis**

3

4 Catalina Núñez,<sup>1,2</sup> Jaime Delgado,<sup>3</sup> Michael Barkham,<sup>3</sup> Alex Behn<sup>1,2\*</sup>

5

6 <sup>1</sup> Millennium Institute for Depression and Personality Research (MIDAP), Chile

7 <sup>2</sup> School of Psychology, Pontificia Universidad Católica de Chile, Santiago, Chile

8 <sup>3</sup> Clinical and Applied Psychology Unit, School of Psychology, University of Sheffield,  
9 Sheffield, S1 2LT, UK

10 \*Corresponding author: Alex Behn School of Psychology, Pontificia Universidad Católica de  
11 Chile, Av. Vicuña Mackenna 4860, Santiago, Chile.

12 *E-mail address:* [albehn@uc.cl](mailto:albehn@uc.cl)

13

14 **RUNNING TITLE:** Depression Profiles and Network Analysis

15

This peer-reviewed article has been accepted for publication but not yet copyedited or typeset, and so may be subject to change during the production process. The article is considered published and may be cited using its DOI.

This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.

16

**Abstract**

17 **Background:** Depression is one of the most prevalent mental health conditions in the world.  
18 However, the heterogeneity of depression has presented obstacles for research concerning  
19 disease mechanisms, treatment indication, and personalization. So far, depression heterogeneity  
20 research has mainly used latent variable modeling, assuming a latent cause, that overlooks the  
21 possibility that symptoms might interact and reinforce each other. The current study used  
22 network analysis to analyze and compare profiles of depressive symptoms present in community  
23 samples, considering the relationship between symptoms.

24 **Methods:** Cross-sectional measures of depression using the Patient Health Questionnaire-9  
25 (PHQ-9) were collected from community samples using data from participants scoring above a  
26 clinical threshold of  $\geq 10$  points (N=2,023; 73.9% female; mean age 49.87, SD= 17.40). Data  
27 analysis followed three steps. First, a profiling algorithm was implemented to identify all  
28 possible symptom profiles by dichotomizing each PHQ-9 item. Second, the most prevalent  
29 symptom profiles were identified in the sample. Third, network analysis for the most prevalent  
30 symptom profiles was carried out to identify the centrality and covariance of symptoms.

31 **Results:** Of 382 theoretically possible depression profiles, only 167 were present in the sample.  
32 Furthermore, 55.6% of the symptom profiles present in the sample were represented by only  
33 eight profiles. Network analysis showed that the network and symptoms relationship varied  
34 across the profiles.

35 **Conclusions:** Findings indicate that the vast number of theoretical possible ways to meet the  
36 criteria for major depressive disorder is significantly reduced in empirical samples, and that the  
37 most common profiles of symptoms have different networks and connectivity patterns. Scientific

38 and clinical consequences of these findings are discussed in the context of the limitations of this  
39 study.

40 *Keywords:* Network Analysis, Depression Heterogeneity, Depression Profiles

41

**Introduction**42 *Why is depression a public health problem?*

43           Depression is the most prevalent mental health problem in the world affecting 4.7% of  
44 the global population [1]. It has been classified as a public health problem due to its impact on  
45 quality of life, work productivity, and mortality risk [2]. Despite global efforts to understand and  
46 treat depression, its incidence has actually increased by 49% between 1990 and 2017 [3].  
47 Currently, it is the third leading cause of disease burden and the single highest contributing  
48 factor to global disability [3,4]. The impact of depression is not only felt by individuals, but also  
49 by their families and communities, who suffer a direct cost related to treatment and an indirect  
50 cost linked to an individual's reduced functional capacity [5,6]. Studies estimate that, when  
51 diagnosed, depression could cost \$6,200 per person per year [7], while undiagnosed and  
52 untreated depression contributes to an even more significant burden of illness, increasing  
53 personal and societal costs [8]. Indeed, longer periods of undiagnosed and untreated depression  
54 lead to negative outcomes including poorer treatment response and lower remission rates [9],  
55 more severe cognitive impairment [10], and overall to poorer illness trajectories [11].

56

57 *What does heterogeneity in depression mean?*

58           Ever since the publication of DSM-III forty years ago, the field of healthcare has mainly  
59 conceived depression as a homogeneous, distinct, and robust diagnostic category, outlined  
60 broadly in the polythetic system of the DSM as Major Depressive Disorder (MDD) [12]. The  
61 DSM's polythetic system masks a significant amount of syndromic heterogeneity, allowing for  
62 multiple combinations of symptoms to exist under the same diagnostic label [13]. As a

63 consequence, the diagnostic criteria of MDD has led to the classification of people with only  
64 some or even no symptoms in common into the same broad category, ignoring the specific  
65 presentation of their symptoms and the interactions between specific symptoms [14–16].

66

67 *Consequences of heterogeneity in depression on treatment outcomes*

68 Failure to consider heterogeneity in depression has impacted the understanding of  
69 etiological mechanisms and their physiological correlates [17–20] and it has also limited the  
70 effectiveness of treatments [21]. Thus, it is highly important that research should consider the  
71 heterogeneity of MDD in order to better address etiological processes and to implement smarter  
72 and personalized treatment strategies [16].

73 It is estimated that nearly 85% of people who recover from MDD suffer a second episode  
74 within 15 years, and that each additional MDD episode increases the risk of relapse by 18%  
75 [22]. In addition, for 30% of patients diagnosed with MDD, symptoms do not remit despite  
76 varied treatment attempts [2], with sleep problems and fatigue being the most prevalent residual  
77 symptoms [23]. This highlights that patients will not respond similarly to different treatments  
78 for MDD [24,25]. Even though clinicians typically adjust treatments to their specific patients,  
79 often guidelines recommend treatments packages that are delivered to the ‘average depressed  
80 patient’ and insufficient research has considered what are the specific modifications that should  
81 be implemented to optimize a treatment for a particular subtype of depression. Thus, treatments  
82 may yield sub-optimal effects, whereas parsing out heterogeneity in depression could enable the  
83 design of evidence-based personalization strategies for treatments, thus leading to possible  
84 improved patient outcomes.

85

86 *What are we missing by not looking at symptom-level heterogeneity?*

87         Research has typically approached depression as a common cause for diverse symptoms  
88 and assumed that these symptoms are independent and have equal importance [14,26,27].  
89 However, such a strategy has paid less attention to the interaction and mutual reinforcement  
90 between symptoms [28]. This is a problem, considering that researchers have been attempting to  
91 find associations between different symptoms of depression and distinct risk factors [29,30],  
92 different gene polymorphisms [31], and different responses to treatment [32,33]. Moreover,  
93 different symptoms have been associated with varying impacts on disability, with depressed  
94 mood and concentration problems being the most disabling symptoms [34]. This is consistent  
95 with research showing that patients who receive their optimal treatment (considering their  
96 specific symptoms and personal characteristics) had clinically significant improvements in  
97 depression [e.g., 21,35,36].

98         An examination of symptom level heterogeneity in depression may also be crucial in  
99 improving our understanding of differential developmental pathways towards psychopathology  
100 from the perspective of equifinality and multifinality [37]. Indeed, by using a homogeneous  
101 conceptualization of depression, different pathways to illness may be masked and thus, relevant  
102 opportunities for prevention and personalization lost. Heterogeneity research in depression can  
103 move the field towards a more person-centered approach that recognizes the relevance of  
104 different developmental pathways to illness that may be related to or represented by different  
105 profiles of depression [38].

106           Until now, depression has been studied through theoretical and empirical approaches that  
107 have supplied evidence to its heterogeneity, identifying profiles of symptoms that may help map  
108 out heterogeneity [2,16]. However, although empirical research has found profiles related to the  
109 composition as well as severity of symptom profiles [e.g., 13, 39], it does not consider the  
110 relation *between* symptoms within emerging profiles. Furthermore, studies show that not all  
111 theoretically possible profiles of symptoms are actually present in clinical samples [13,39]. Still,  
112 these studies have focused on the presence and prevalence of different profiles, leaving aside  
113 how the symptoms are related to each other as an interrelated system. There are also studies that  
114 are focused on seeing the interaction between depressive symptoms using network analysis and  
115 other analytic strategies, but they usually analyze the depressive symptoms on total samples  
116 without considering different profiles and interrelated networks between profiles [40].

117           As a result, it is not known which symptoms are present in each profile, how they are  
118 related, or what the structure of the network of symptoms is like. In addition, we do not  
119 understand how the empirical frequency of theoretical profiles differs when considering  
120 community samples that include both help-seeking and non help-seeking individuals. The  
121 current study is the first, to our knowledge, to examine the network structure and interactions  
122 between symptoms on different symptom profiles of depression.

123

124

## Methods

### 125 Participants

126           The study used secondary data derived from three community studies with nationally  
127 representative samples: (1) the Chilean Longitudinal Social Survey (ELSOC); (2) the

128 Longitudinal Study of Intercultural Relations (ELRI); and (3) the Social Protection Survey  
129 (EPS). These three studies were carried out between 2016 and 2020 and used multi-stage,  
130 stratified, and probabilistic sampling. The inclusion criteria for the sampling of these studies  
131 focused on female and male residents in urban areas, aged 18 to 99, and located in 13 different  
132 (blinded for review). All three studies used the Patient Health Questionnaire (PHQ-9) to  
133 measure depression symptoms. Only participants with clinically significant depressive  
134 symptoms ( $\text{PHQ-9} \geq 10$ ) were included in the present study. Of a total sample of 13,367  
135 participants, 2,023 (15.13%) had a PHQ-9 score of 10 or above.

### 136 **Measures and data sources**

137 The Spanish-language version version of the PHQ-9 was used to measure depressive  
138 symptoms [PHQ-9, 41]. It is a nine-item scale in which each item represents a DSM symptom  
139 criterion. Participants are asked to report whether they have experienced the symptom in the last  
140 two weeks on a Likert scale ranging from 0 to 3, where 0 is "not at all," and 3 is "almost every  
141 day," resulting in a total score ranging from 0 to 27 points [42]. The PHQ-9 was designed to  
142 screen for depression and has shown that scores  $\geq 10$  have a sensitivity of 88% and specificity of  
143 88% for major depressive disorder compared to semi-structured interviews [43]. A diagnostic  
144 cut-off of  $\geq 10$  is recommended for the detection of MDD, the criteria for classifying severity  
145 levels of depression according the PHQ-9 are "moderate" for scores of 14 or below, "moderately  
146 severe" for scores ranging between 15 and 19, and "severe depression" for scores of 20 or above.  
147 [43].

### 148 **Statistical Analysis**

149 Descriptive statistics were generated for the total sample. To test for sex differences in  
150 total PHQ-9 means, a t-test for independent samples was used.

151

152 All possible symptom profiles were identified for PHQ-9 scores equal or higher than 10  
153 points (i.e., clinical sample) using an algorithm of combinatorial optimization. This was  
154 calculated using the formula  ${}^n C_r = \frac{n!}{r!(n-r)!}$  (for formula estimation see supplementary material),  
155 that allows calculation of the number of ways of selecting  $r$  objects out of  $n$  different objects  
156 [44]. The estimation resulted in 382 possible symptom combinations.

157

#### 158 *Theoretical symptom profile analysis*

159 All possible symptom combinations were analyzed for the PHQ-9 using a profiling  
160 algorithm developed by Banyard et al. [45]. In this algorithm, individual item responses to the  
161 PHQ-9 were dichotomized, and coded as either "1" if a symptom was present (a score of 1-3) or  
162 "0" if a symptom was absent (a score of 0). Using conditionals, each individual response was  
163 matched to their corresponding profile (for details, see supplementary material). Different  
164 theoretical profiles of depressive symptomatology could thus be constructed yielding a score of  
165 10 or above 382 possible theoretical profiles, for details see supplementary material. Each  
166 theoretical profile was assigned a number and its relative frequency was determined using  
167 patient-level data, using a syntax that matches each participant's PHQ-9 responses to each of the  
168 possible 382 theoretical symptom profile combinations. This is a method that prioritizes the  
169 identification of *qualitatively distinctive* symptom profiles by emphasizing the absence-presence  
170 of symptoms rather than emphasizing *quantitative differences* in their relative scores across each

171 Likert scale. This method was selected to maximize the probability of identifying qualitatively  
172 different profiles, since prior research using continuous Likert-scale scores to identify latent  
173 classes consistently show that such a method mainly parses cases into quantitatively distinctive  
174 subgroups of cases with low-moderate-severe depression [e.g., see 27,46].

175

176

### 177 *Network analysis*

178 Network analysis was used to examine the most prevalent profiles within the relationship  
179 between symptoms, so that within a particular network, each *node* represents a PHQ-9 item (i.e.,  
180 a depression symptom) and each *edge* represents the partial correlation between two symptoms.  
181 Network estimation was conducted using Pairwise Markov Random Fields to calculate a  
182 nondirected weighted network structure, and a Gaussian Graphical Model to estimate networks  
183 with continuous data variables. By using the continuous item scores as inputs into the network  
184 model, we were able to comprehensively identify *qualitatively distinctive* profiles (through the  
185 prior step of analysis) while examining their *quantitative distinctive* network structures using the  
186 full range of Likert scale responses.

187 The Fruchterman-Reingold algorithm was used to calculate the optimal layout of the  
188 networks and to visualize more strongly connected nodes [47]. False-positive relations were  
189 excluded by using the 'graphical least absolute shrinkage and selection operator' (GLASSO)  
190 method, a statistical regularization technique, to increase the specificity of the network [48]. Due  
191 to recent developments in network analysis discussing the use of regularized versus non-  
192 regularized techniques for the estimation of psychopathology networks [49–51], both types of  
193 analysis were conducted, and results are presented in supplementary materials. Finally, the

194 extended Bayesian information criterion (EBIC) was used to select the best-fitting model  
195 (hyperparameters  $\gamma = 0.5$  and  $\lambda = 0.01$ ).

196 Strength centrality indexes were calculated for each network. This measure takes the  
197 sum of all absolute edge weights to which a node is directly connected [52]. To estimate the  
198 network stability, and considering the sample size for each depression symptom profile, a non-  
199 parametric bootstrapping procedure was used with 1,000 sample simulations providing results  
200 related to the edge-weight accuracy on each network [53,54]. A case-dropping subset bootstrap  
201 was performed for the estimation of the centrality stability, which estimates a correlation  
202 stability coefficient (CS-coefficient) representing the maximum proportion of the sample that  
203 can be dropped and maintaining a 95% probability of a correlation between the original  
204 centrality indices and the centrality metric equal or higher to 0.7. Thus, the centrality metric is  
205 considered interpretable when the CS-coefficient is above 0.25 [53]. All the analyses were  
206 performed using '*qgraph*' (55,56) and '*bootnet*' packages [53,54] on R studio version 4.0.0 [57].

207

## 208 **Results**

### 209 **Sample characteristics**

210 The total sample included PHQ-9 data from  $N=2,023$  participants that had clinically  
211 significant depression symptoms ( $\text{PHQ-9} \geq 10$ ). Overall, 73.9% ( $n = 1,495$ ) of participants were  
212 female, the mean age of the total sample was 49.87 ( $SD = 17.40$ ) years, and the mean PHQ-9  
213 score was 14.7 ( $SD = 4.36$ ). Approximately 57.7% of participants would be considered  
214 moderately depressed ( $n = 1,168$ ), 26.2% ( $n = 531$ ) had moderately severe scores, and 16.0% ( $n$

215 = 324) had severe depression. Supplementary Table 1 provides further sample characteristics  
216 and details on item-level means and frequencies.

217

218       There were no statistically significant differences between female and male participants  
219 regarding their mean depression severity scores ( $t_{(2021)} = -1.51, p = .13$ ). In total, 35.5% of  
220 participants reported having received a depression diagnosis, and 84.4% of participants who  
221 received a diagnosis were women. Approximately 32% (649) reported having previously  
222 received or currently were receiving treatment for depression at the time of the assessment.  
223 Among participants with a past or current history of treatment, 83.6% (551) were female.

224

### 225 **Symptom profiles**

226       Of the 382 theoretically possible profiles of depressive symptoms operationalized by the  
227 profiling algorithm for scores of 10 and above on the PHQ-9, 167 were actually present in the  
228 sample. However, more than half of all cases present in the sample (55.6%) were accounted by  
229 only 8 symptom profiles. Of all 167 profiles present in the sample, the most frequent was profile  
230 1 ( $n=510$ ), a “typical” depression profile that includes all 9 symptoms of depression measured  
231 by the PHQ-9 (all 9 items are positive) and had a frequency of 25.2% of the sample. The mean  
232 age for profile 1 was 49.87 ( $SD= 17.40$ ) and the mean PHQ-9 score within this profile was 18.6  
233 ( $SD = 4.85$ ).

234       The second most frequent profile was profile 2 ( $n=205$ ), a profile that includes all  
235 symptoms, except for suicidal ideation (item 9), which accounted for 10.1% of cases present in  
236 the sample. The mean age for profile 2 was 45.68 ( $SD= 17.41$ ) and the mean PHQ-9 score was  
237 14.88 ( $SD = 4.09$ ).



259           The network of profile 1 is visualized in Figure 1 and shows a strong positive connection  
260 between low mood and anhedonia ( $pr = 0.30$ ) and also between sleep problems and low energy  
261 ( $pr = 0.26$ ). Also, there is a community of tightly interrelated symptoms including suicidal  
262 ideation- concentration problems ( $pr = 0.24$ ), suicidal ideation- changes in psychomotor  
263 functioning (agitation or retardation) ( $pr = 0.20$ ), concentration problems- changes in  
264 psychomotor functioning ( $pr = 0.20$ ).

265           The nodes with the highest strength centrality in profile 1 were: low mood, low energy  
266 and concentration problems. The least central nodes in terms of strength centrality were  
267 anhedonia and sleep problems. Node strength centrality demonstrated an interpretable level of  
268 stability ( $CS (cor = 0.7) = 0.36$ ). Details of the centrality stability test are shown in  
269 Supplementary Figures 1 and 2.

270

271 *Profile 2: Typical depression without suicidal ideation*

272           This profile included all typical depression symptoms except for suicidal ideation.

273

274 Figure 2. Network of symptoms and centrality plot for profile 2.

275

276

**INSERT-FIGURE-2**

277

278

279 Note: The centrality plot shows standardized strength indices.

280

281           The network of profile 2 is visualized in Figure 2 and shows a strong positive connection  
282 between low mood and anhedonia ( $pr = 0.27$ ), low mood and low energy ( $pr = 0.26$ ), and low  
283 mood and worthlessness ( $pr = 0.18$ ). The nodes with the highest strength centrality were low  
284 mood, low energy and worthlessness. The least central nodes in terms of strength centrality were  
285 psychomotor functioning and anhedonia. These data must be interpreted with caution because  
286 node strength centrality demonstrated low stability ( $CS(\text{cor} = 0.7) = 0.12$ ). See details of the  
287 centrality stability test in Supplementary Figures 4 and 5.

288

289 *Profile 3: All depressive symptoms except for psychomotor functioning and suicidal ideation*

290

291           This profile includes all PHQ-9 symptoms except for suicidal ideation and changes  
292 related to psychomotor functioning.

293

294 Figure 3. Network of symptoms and centrality plot for profile 3.

295

296

**INSERT-FIGURE-3**

297

298

299 Note: The centrality plot shows standardized strength indices.

300           The network of profile 3 is visualized in Figure 3. Profile 3 was the third most frequent  
301 in the sample. Due to the small sample size ( $n = 81$ ) this network was estimated using a threshold  
302 of  $\leq 0.05$  instead of applying the GLASSO method (which did not converge in this subgroup).

303 The network shows a strong positive connection between low mood and low energy ( $pr = 0.37$ ),

304 low mood and anhedonia ( $pr = 0.32$ ), sleep problems and anhedonia ( $pr = 0.23$ ), sleep problems  
305 and low energy ( $pr = 0.22$ ), appetite and worthlessness ( $pr = 0.23$ ).

306 The nodes with the highest strength centrality were low energy, low mood, and  
307 worthlessness. In contrast, the nodes with the least strength centrality were sleep problems and  
308 appetite changes. However, these data must be interpreted with caution because node strength  
309 centrality demonstrated low stability related to the sample size ( $CS(\text{cor} = 0.7) = 0.21$ ). For  
310 details on the centrality stability test and accuracy (see Supplementary Figures 7 and 8).

311

312 Results indicated that node centrality varied across the most frequent profiles of  
313 depression (see Figure 4 for a comparison). Consistently, the most central symptoms were low  
314 mood and low energy, and the less central symptoms were anhedonia, change in the  
315 psychomotor functioning, and appetite changes.

316

317 Figure 4. Strength centrality rankings indices for the three most prevalent profiles.

318

319 **INSERT-FIGURE-4**

320 Note: Numbers indicate Strength centrality rankings. Profile 1: all of the typical symptoms of  
321 depression; Profile 2: typical depression without suicidal ideation; Profile 3: All depressive  
322 symptoms except for psychomotor functioning and suicidal ideation. Figure adapted with  
323 permission from Malgaroli et al. [40] and license provided by Elsevier.

324

325

## Conclusions

326

327           The present study identified different depressive symptom profiles and examined their  
328 network structure using PHQ-9 data from participants with clinically relevant depressive  
329 symptoms drawn from three community samples. Results show that 167 of the 382 theoretically  
330 possible symptom combinations were present in the sample, and 55.6% of all profiles were  
331 accounted for by only 8 profiles. The most frequent symptom profile included all typical  
332 symptoms of depression measured by the PHQ-9 (25.2%). These results are consistent with  
333 studies that applied a similar approach using patient-level data, which show that many cases  
334 display similar symptom profiles. For example, Zimmerman et al. [13] similarly found in a  
335 community sample that out of the 227 symptom combinations calculated using semi-structured  
336 interviews (SCID-I), just 170 were empirically observed and concluded that nine combination  
337 profiles accounted for the depression symptoms of 40% of patients. These findings align with  
338 those of Park et al. [39], who identified in a clinical sample 119 symptom combinations within  
339 their sample. Both studies, using a different approach from the one used in the present study,  
340 concluded that combinatorial patterns with all nine symptoms of depression were the most  
341 prevalent in samples from the USA and South Korea [13,39]. Overall, the extent of diagnostic  
342 heterogeneity observed empirically within clinical and community-based samples is lower than  
343 has been previously suggested based on theoretical arguments [e.g., 16].

344

345           The three most prevalent profiles showed similar mean levels of overall symptom  
346 severity on the PHQ-9 total score. However, there were evident differences in their centrality  
347 indices and in the interrelations between symptoms. This is clinically relevant, considering that  
348 one of these profiles shows suicidal ideation and is rated with the same severity as the other

349 profiles, supporting the idea that looking at total scores in scales omits important qualitative  
350 differences between symptoms concerning their hierarchy and clinical relevance [28,58].

351

352         Regarding the relationship between symptoms, there are several differences between the  
353 profiles related to the centrality indices and the connection between them. The most common  
354 profile, namely profile 1, showed a strong relationship between concentration problems, suicidal  
355 ideation, and psychomotor functioning, with concentration problems constituting a rather strong  
356 node within this profile. This is different to those profiles that do not include suicidal ideation.  
357 These results are in line with those reported in two meta-analyses that found an association  
358 between the attentional process and suicidal spectrum behaviors [59,60] . Thus, this profile could  
359 be relevant in identify vulnerable people in the population because it has been highlighted that  
360 sad mood and concentration problems, the two most central symptoms for this profile, are the  
361 most disabling symptoms of depression [34].

362

363         Another difference between the profiles is present in profile 2, which shows a strong  
364 connection between low mood, low energy, and self-perception. In this profile, with all of the  
365 symptoms except for suicidal ideation, worthlessness takes a key role in comparison to profile 1  
366 which includes all of the symptoms. On the other hand, in profile 3 worthlessness is strongly  
367 related to changes in appetite, which is unique to this profile. Profile 3 is characterized by the  
368 centrality of low energy which is different from profiles 1 and 2, where low mood is the most  
369 central symptom.

370

371 In the most frequent profiles of depressive symptoms, results show that low mood and  
372 low energy are consistently among the three most central symptoms; this is similar to the results  
373 reported in a systematic review that considered the results of 58 cross-sectional depression  
374 networks. Interestingly, anhedonia does not appear as a central node on these profile networks,  
375 even though it has a strong positive connection with low mood ( $pr = 0.30, 0.27, 0.21$ ), showing a  
376 consistent relationship on the three profiles analyzed. This is also consistent with previous  
377 studies that found the connection between low mood and anhedonia was the networks' most  
378 frequent and robust edge [40]. This is theoretically interesting, considering that anhedonia has  
379 been conceived as a main symptom according to the DSM diagnostic criteria for major  
380 depressive disorder.

381  
382 In terms of methodology, there are limitations related to the sample sizes for each profile  
383 subsample that must be considered when interpreting these results. The estimation method could  
384 impact the visualization of the networks for small sample sizes, generating networks that overfit  
385 to data and impacting the stability of the centrality indexes [53]. Another limitation of this study  
386 is the use of cross-sectional data, which provides only a static vision of the profile symptoms that  
387 could change over time. Future studies should consider these limitations and explore the  
388 relationship between symptoms over time using longitudinal designs with repeated measures.  
389 Also, it could be relevant to understand the possible directional influence between the symptoms  
390 considering time-series data. An additional limitation of this study, as well as depression  
391 heterogeneity research, that has been shown in previous studies [61], is that different instruments  
392 can assess different symptoms of depression. Therefore, this study captures the heterogeneity of  
393 the specific screening instrument that was used, and other instruments that capture additional

394 symptoms or that phrase the same symptoms differently may yield different heterogeneity  
395 profiles. Consequently, no claims can be made about substantive heterogeneity as it occurs in  
396 nature (i.e., carving nature at its joints) but rather as it emerges from the use of the PHQ-9, a  
397 widely used screening measure and recommended as a preferred measure for the screening of  
398 depression [62,63]. It is important to acknowledge that finding common ground for the screening  
399 of depression by utilizing one instrument also may have a negative impact on the efforts to map  
400 out heterogeneity; it is easier to aggregate findings from different studies but all researchers are  
401 looking through the same lens, that could narrow the comprehension of depression [64,65].

402

403       Even with these limitations, this study is the first to our knowledge that combined the  
404 identification of qualitatively distinctive symptom profiles and examined the network structure  
405 of such profiles using network analyses. Previous network analysis research has shown the  
406 relevance of investigating the interrelations between symptoms of depression [40]. While the  
407 present results support this approach, they also expand previous research about network analysis  
408 and depression and provide empirical support regarding the relevance of looking at the different  
409 profiles and the different relations between symptoms for each one. Also, these results could be  
410 relevant considering treatment personalization.

411

#### 412 **Author Statement Contributors**

413 Conceptualization: C.N., A.B; Data curation: C.N., A.B; Formal analysis: C.N. with the support  
414 of A.B.; Data visualization: C.N, A.B , Writing—original draft: C.N., A.B., J.D., M.B. ;  
415 Writing—review & editing: C.N., A.B., J.D., M.B. All authors gave the final approval.

416

417 **Acknowledgements**

418 We acknowledge the efforts to promote open data availability from the Centre for Social Conflict  
419 and Cohesion Studies (COES), the Center for Intercultural and Indigenous Studies (CIIR) and  
420 the Social Protection Survey (EPS) from the Subsecretaría de Previsión Social, Gobierno de  
421 Chile.

422

423 **Financial Support**

424

425 This work was funded by the National Agency for Research and Development, Chile (ANID) /  
426 Scholarship National Doctoral Grant (grant number 21200732). International Network for the  
427 Study of the Heterogeneity of Depression (grant number PCI-ANID REDES180140), and  
428 Millennium Institute for Depression and Personality Research Personality (grant number  
429 MIDAP ICS13\_005).

430

431 **Conflicts of Interest**

432 The authors declare that they have no known competing interests that could have appeared to  
433 influence the work reported in this paper.

434

435

**References**

- 436 [1] Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, et al. Global variation  
437 in the prevalence and incidence of major depressive disorder: A systematic review of the  
438 epidemiological literature. *Psychol Med.* 2013;43(3):471–81.
- 439 [2] Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. Major depressive  
440 disorder. *Nat Rev Dis Primers* [Internet]. 2016;2(Mdd):1–21. Available from:  
441 <http://dx.doi.org/10.1038/nrdp.2016.65>
- 442 [3] Liu Q, He H, Yang J, Feng X, Zhao F, Lyu J. Changes in the global burden of depression  
443 from 1990 to 2017: Findings from the Global Burden of Disease study. *J Psychiatr Res*  
444 [Internet]. 2020;126(August):134–40. Available from:  
445 <https://doi.org/10.1016/j.jpsychires.2019.08.002>
- 446 [4] Eder J, Dom G, Gorwood P, Kärkkäinen H, Decraene A, Kumpf U, et al. Improving  
447 mental health care in depression: A call for action. *European Psychiatry.* 2023 Aug  
448 3;66(1):e65.
- 449 [5] Kleine-Budde K, Müller R, Kawohl W, Bramesfeld A, Moock J, Rössler W. The cost of  
450 depression - A cost analysis from a large database. *J Affect Disord.* 2013;147(1–3):137–  
451 43.
- 452 [6] Wang PS, Patrick A, Avorn J, Azocar F, Ludman E, McCulloch J, et al. The costs and  
453 benefits of enhanced depression care to employers. *Arch Gen Psychiatry.*  
454 2006;63(12):1345–53.
- 455 [7] Luppá M, Heinrich S, Angermeyer MC, König HH, Riedel-Heller SG. Cost-of-illness  
456 studies of depression. A systematic review. *J Affect Disord.* 2007;98(1–2):29–43.

- 457 [8] Thilina D, Yadurshini R. The Economic Burden of Depression: Why We Should Invest in  
458 Treatment and Prevention? *International Journal of Clinical Studies and Medical Case*  
459 *Reports* [Internet]. 2020 Sep 17;4(5):29–43. Available from:  
460 <https://ijclinmedcasereports.com/ijcmcr-ed-id-00096/>
- 461 [9] Ghio L, Gotelli S, Marcenaro M, Amore M, Natta W. Duration of untreated illness and  
462 outcomes in unipolar depression: A systematic review and meta-analysis. *J Affect Disord.*  
463 2014 Jan;152–154:45–51.
- 464 [10] Galimberti C, Bosi MF, Volontè M, Giordano F, Dell’Osso B, Viganò CA. Duration of  
465 untreated illness and depression severity are associated with cognitive impairment in  
466 mood disorders. *Int J Psychiatry Clin Pract.* 2020 Sep 1;24(3):227–35.
- 467 [11] Altamura AC, Dell’Osso B, Mundo E, Dell’Osso L. Duration of untreated illness in major  
468 depressive disorder: a naturalistic study. *Int J Clin Pract.* 2007 Sep 14;61(10):1697–700.
- 469 [12] American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*  
470 [Internet]. 5ta ed. American Psychiatric Association; 2013. Available from:  
471 <https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890425596>
- 472 [13] Zimmerman M, Ellison W, Young D, Chelminski I, Dalrymple K. How many different  
473 ways do patients meet the diagnostic criteria for major depressive disorder? *Compr*  
474 *Psychiatry.* 2015;56:29–34.
- 475 [14] Borsboom D, Cramer AOJ. Network analysis: An integrative approach to the structure of  
476 psychopathology. *Annu Rev Clin Psychol.* 2013;9:91–121.
- 477 [15] Bringmann LF, Lemmens LHJM, Huibers MJH, Borsboom D, Tuerlinckx F. Revealing  
478 the dynamic network structure of the Beck Depression Inventory-II. *Psychol Med.*  
479 2015;45(4):747–57.

- 480 [16] Fried EI, Nesse RM. Depression is not a consistent syndrome: An investigation of unique  
481 symptom patterns in the STAR\*D study. *J Affect Disord* [Internet]. 2015;172:96–102.  
482 Available from: <http://dx.doi.org/10.1016/j.jad.2014.10.010>
- 483 [17] Buch AM, Liston C. Dissecting diagnostic heterogeneity in depression by integrating  
484 neuroimaging and genetics. *Neuropsychopharmacology* [Internet]. 2021 Jan;46(1):156–  
485 75. Available from:  
486 [http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2020-68345-](http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2020-68345-001&lang=es&site=ehost-live)  
487 [001&lang=es&site=ehost-live](http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2020-68345-001&lang=es&site=ehost-live)
- 488 [18] Cai N, Choi KW, Fried EI. Reviewing the genetics of heterogeneity in depression:  
489 operationalizations, manifestations and etiologies. *Hum Mol Genet*. 2020;29(June):R10–8.
- 490 [19] Goldstein BL, Klein DN. A review of selected candidate endophenotypes for depression.  
491 *Clin Psychol Rev* [Internet]. 2014;34(5):417–27. Available from:  
492 <http://dx.doi.org/10.1016/j.cpr.2014.06.003>
- 493 [20] Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major  
494 depression. *Neuropsychopharmacology*. 2004;29(10):1765–81.
- 495 [21] DeRubeis RJ, Cohen ZD, Forand NR, Fournier JC, Gelfand LA, Lorenzo-Luaces L. The  
496 Personalized Advantage Index: Translating Research on Prediction into Individualized  
497 Treatment Recommendations. A Demonstration. Cho WCS, editor. *PLoS One* [Internet].  
498 2014 Jan 8;9(1):e83875. Available from:  
499 <https://dx.plos.org/10.1371/journal.pone.0083875>
- 500 [22] Cuijpers P, Andersson G, Donker T, Van Straten A. Psychological treatment of  
501 depression: Results of a series of meta-analyses. *Nord J Psychiatry*. 2011;65(6):354–64.

- 502 [23] Menza M, Marin H, Opper RS. Residual Symptoms in Depression. *J Clin Psychiatry*.  
503 2003 May 15;64(5):516–23.
- 504 [24] Luyten P, Lowyck B, Blatt SJ. Mechanisms of Change Through the Lens of Two-  
505 Polarities Models of Personality Development: State of the Art and New Directions.  
506 *Psychoanal Inq [Internet]*. 2017;37(3):179–90. Available from:  
507 <http://dx.doi.org/10.1080/07351690.2017.1285187>
- 508 [25] Arjmand S, Grassi-Oliveira R, Wegener G. Rethinking treatment-resistant depression to  
509 quasi-tenacious depression. *European Psychiatry*. 2023 Jan 12;66(1):e14.
- 510 [26] Borsboom D. A network theory of mental disorders. *World Psychiatry [Internet]*. 2017  
511 Feb;16(1):5–13. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/wps.20375>
- 512 [27] Van Loo HM, De Jonge P, Romeijn JW, Kessler RC, Schoevers RA. Data-driven subtypes  
513 of major depressive disorder: A systematic review. *BMC Med*. 2012;10.
- 514 [28] Fried E. Moving forward: how depression heterogeneity hinders progress in treatment and  
515 research. *Expert Rev Neurother [Internet]*. 2017;17(5):423–5. Available from:  
516 <http://dx.doi.org/10.1080/14737175.2017.1307737>
- 517 [29] Fried EI. Problematic assumptions have slowed down depression research: Why  
518 symptoms, not syndromes are the way forward. *Front Psychol*. 2015;6(MAR):1–11.
- 519 [30] Lux V, Kendler KS. Deconstructing major depression: a validation study of the DSM-IV  
520 symptomatic criteria. *Psychol Med [Internet]*. 2010 Oct 11;40(10):1679–90. Available  
521 from:  
522 [https://www.cambridge.org/core/product/identifier/S0033291709992157/type/journal\\_arti](https://www.cambridge.org/core/product/identifier/S0033291709992157/type/journal_article)  
523 cle

- 524 [31] Myung W, Song J, Lim SW, Won HH, Kim S, Lee Y, et al. Genetic association study of  
525 individual symptoms in depression. *Psychiatry Res* [Internet]. 2012 Aug;198(3):400–6.  
526 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0165178111008213>
- 527 [32] Chekroud AM, Zotti RJ, Shehzad Z, Gueorguieva R, Johnson MK, Trivedi MH, et al.  
528 Cross-trial prediction of treatment outcome in depression: a machine learning approach.  
529 *Lancet Psychiatry* [Internet]. 2016 Mar;3(3):243–50. Available from:  
530 <https://linkinghub.elsevier.com/retrieve/pii/S221503661500471X>
- 531 [33] Pigott HE, Leventhal AM, Alter GS, Boren JJ. Efficacy and effectiveness of  
532 antidepressants: Current status of research. *Psychother Psychosom*. 2010;79(5):267–79.
- 533 [34] Fried EI, Nesse RM. The Impact of Individual Depressive Symptoms on Impairment of  
534 Psychosocial Functioning. Gong Q, editor. *PLoS One* [Internet]. 2014 Feb  
535 28;9(2):e90311. Available from: <https://dx.plos.org/10.1371/journal.pone.0090311>
- 536 [35] Kappelmann N, Rein M, Fietz J, Mayberg HS, Craighead WE, Dunlop BW, et al.  
537 Psychotherapy or medication for depression? Using individual symptom meta-analyses to  
538 derive a Symptom-Oriented Therapy (SO<sub>r</sub>T) metric for a personalised psychiatry. *BMC*  
539 *Med* [Internet]. 2020 Dec 5;18(1):170. Available from:  
540 <https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-020-01623-9>
- 541 [36] Webb CA, Trivedi MH, Cohen ZD, Dillon DG, Fournier JC, Goer F, et al. Personalized  
542 prediction of antidepressant v. placebo response: evidence from the EMBARC study.  
543 *Psychol Med* [Internet]. 2019 May 2;49(07):1118–27. Available from:  
544 [https://www.cambridge.org/core/product/identifier/S0033291718001708/type/journal\\_arti](https://www.cambridge.org/core/product/identifier/S0033291718001708/type/journal_article)  
545 cle

- 546 [37] Fonagy P, Luyten P, Allison E, Campbell C. Taking stock to move forward: Where the  
547 field of developmental psychopathology might be heading. *Dev Psychopathol.* 2024 Feb  
548 23;1–10.
- 549 [38] Handley ED, Duprey EB, Russotti J, Levin RY, Warmingham JM. Person-centered  
550 methods to advance developmental psychopathology. *Dev Psychopathol.* 2024 Feb 28;1–  
551 9.
- 552 [39] Park SC, Kim JM, Jun TY, Lee MS, Kim JB, Yim HW, et al. How many different  
553 symptom combinations fulfil the diagnostic criteria for major depressive disorder? Results  
554 from the CRESCEND study. *Nord J Psychiatry.* 2017;71(3):217–22.
- 555 [40] Malgaroli M, Calderon A, Bonanno GA. Networks of major depressive disorder: A  
556 systematic review. *Clin Psychol Rev [Internet].* 2021 Apr;85:102000. Available from:  
557 <https://linkinghub.elsevier.com/retrieve/pii/S027273582100043X>
- 558 [41] Spitzer R, Kroenke K, Williams J. Validation and utility of a self-report version of  
559 PRIME-MD: the PHQ primary care study. *Primary Care Evaluation of Mental Disorders.*  
560 *Patient Health Questionnaire. JAMA [Internet].* 1999 Nov 10;282(18):1737. Available  
561 from: <http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.282.18.1737>
- 562 [42] Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. *J Gen Intern Med [Internet].* 2001  
563 Sep;16(9):606–13. Available from: [http://link.springer.com/10.1046/j.1525-  
564 1497.2001.016009606.x](http://link.springer.com/10.1046/j.1525-1497.2001.016009606.x)
- 565 [43] Levis B, Benedetti A, Thombs BD. Accuracy of Patient Health Questionnaire-9 (PHQ-9)  
566 for screening to detect major depression: Individual participant data meta-analysis. *The*  
567 *BMJ.* 2019;365.

- 568 [44] Nath Banerjee S. THE FORMULA nCr REVISITED . Journal of Mathematical Sciences  
569 & Computational Mathematics. 2019 Nov 1;1(1):75–8.
- 570 [45] Barnyard H, Delgadillo J. Depression Symptom Heterogeneity and its Relation to  
571 Psychological Treatment Outcomes. 2024.
- 572 [46] Ulbricht CM, Chrysanthopoulou SA, Levin L, Lapane KL. The use of latent class analysis  
573 for identifying subtypes of depression: A systematic review. Psychiatry Res [Internet].  
574 2018 Aug;266(3):228–46. Available from:  
575 <https://linkinghub.elsevier.com/retrieve/pii/S0165178117303128>
- 576 [47] Hevey D. Network analysis: a brief overview and tutorial. Health Psychol Behav Med  
577 [Internet]. 2018 Jan 1;6(1):301–28. Available from:  
578 <https://www.tandfonline.com/doi/full/10.1080/21642850.2018.1521283>
- 579 [48] Epskamp S, Fried EI. A tutorial on regularized partial correlation networks. Psychol  
580 Methods. 2018;23(4):617–34.
- 581 [49] Isvoranu AM, Epskamp S. Which estimation method to choose in network psychometrics?  
582 Deriving guidelines for applied researchers. Psychol Methods. 2023 Aug;28(4):925–46.
- 583 [50] Williams DR, Rhemtulla M, Wysocki AC, Rast P. On Nonregularized Estimation of  
584 Psychological Networks. Multivariate Behav Res. 2019 Sep 3;54(5):719–50.
- 585 [51] Williams DR, Rast P. Back to the basics: Rethinking partial correlation network  
586 methodology. British Journal of Mathematical and Statistical Psychology. 2020 May  
587 17;73(2):187–212.
- 588 [52] Bringmann L, Elmer T, Epskamp S, Krause RW, Schoch D, Wichers M, et al. What do  
589 centrality measures measure in psychological networks? J Abnorm Psychol [Internet].

- 590 2019 Nov;128(8):892–903. Available from:  
591 <http://doi.apa.org/getdoi.cfm?doi=10.1037/abn0000446>
- 592 [53] Epskamp S, Borsboom D, Fried EI. Estimating psychological networks and their  
593 accuracy: A tutorial paper. *Behav Res Methods*. 2018;50(1):195–212.
- 594 [54] Isvoranu AM, Epskamp S, Waldorp LJ, Borsboom D. *Network Psychometrics with R*.  
595 London: Routledge; 2022.
- 596 [55] Epskamp S, Cramer AOJ, Waldorp LJ, Schmittmann VD, Borsboom D. Qgraph: Network  
597 visualizations of relationships in psychometric data. *J Stat Softw*. 2012;48(4).
- 598 [56] Epskamp S, Costantini G, Haslbeck J, Cramer AOJ, Waldorp LJ, Schmittmann VD, et al.  
599 Graph Plotting Methods, Psychometric Data Visualization and Graphical Model  
600 Estimation [Internet]. Version 1.6.9; 2021. Available from: [https://cran.r-](https://cran.r-project.org/web/packages/qgraph/qgraph.pdf)  
601 [project.org/web/packages/qgraph/qgraph.pdf](https://cran.r-project.org/web/packages/qgraph/qgraph.pdf)
- 602 [57] R Core Team. *R: A Language and Environment for Statistical Computing*. 2021.
- 603 [58] Fried EI, Nesse RM. Depression sum-scores don't add up: Why analyzing specific  
604 depression symptoms is essential. *BMC Med*. 2015;13(1):1–11.
- 605 [59] Septier M, Stordeur C, Zhang J, Delorme R, Cortese S. Association between suicidal  
606 spectrum behaviors and Attention-Deficit/Hyperactivity Disorder: A systematic review  
607 and meta-analysis. *Neurosci Biobehav Rev* [Internet]. 2019 Aug;103:109–18. Available  
608 from: <https://linkinghub.elsevier.com/retrieve/pii/S0149763418309412>
- 609 [60] Clauss K, Schafer K, Somohano VC, O'Neil ME, Constans J, Raines AM, et al.  
610 Attentional Risk Factors for Suicidal Thoughts and Behaviors: A Synthesis of the  
611 Literature and Meta-Analysis. *J Psychopathol Behav Assess*. 2023 Dec 28;45(4):1141–53.

- 612 [61] Fried EI. The 52 symptoms of major depression: Lack of content overlap among seven  
613 common depression scales. *J Affect Disord* [Internet]. 2017;208:191–7. Available from:  
614 <http://dx.doi.org/10.1016/j.jad.2016.10.019>
- 615 [62] Farber GK, Gage S, Kemmer D. A Collaborative Effort to Establish Common Metrics for  
616 Use in Mental Health. *JAMA Psychiatry*. 2023 Oct 1;80(10):981.
- 617 [63] Farber GK, Gage S, Kemmer D, White R. Common measures in mental health: a joint  
618 initiative by funders and journals. *Lancet Psychiatry*. 2023 Jun;10(6):465–70.
- 619 [64] Fried EI, Flake JK, Robinaugh DJ. Revisiting the theoretical and methodological  
620 foundations of depression measurement. *Nature Reviews Psychology*. 2022 Apr  
621 14;1(6):358–68.
- 622 [65] Patalay P, Fried EI. Editorial Perspective: Prescribing measures: unintended negative  
623 consequences of mandating standardized mental health measurement. *Journal of Child*  
624 *Psychology and Psychiatry*. 2021 Aug 28;62(8):1032–6.
- 625
- 626
- 627

628 **Table 1**  
 629 Frequency and composition of symptom profiles sample (n=2,023)  
 630  
 631

Symptom Profile	Anhedonia	Low mood	Difficulty with sleep	Energy levels	Appetite	Worthlessness	Ability to concentrate	Psychomotor functioning	Suicidal ideation	%	CF%	N
1										25.2%	25.2%	510
2										10.1%	35.3%	205
3										4.0%	39.3%	81
4										3.9%	43.2%	79
5										3.6%	46.8%	74
6										3.2%	50%	65
7										2.9%	52.9%	60
8										2.7%	55.6%	55

632  
 633  
 634  
 635  
 636

637 **Table 2**  
 638 Descriptive statistics of the 8 most frequent theoretical symptom profiles  
 639  
 640

	Profile 1	Profile 2	Profile 3	Profile 4	Profile 5	Profile 6	Profile 7	Profile 8
	(N = 510)	(N =205)	(N =81)	(N =79)	(N =74)	(N= 65)	(N=60)	(N=55)
<b>Demographics</b>								
Mean Age ( <i>SD</i> )	49.87 (17.40)	45.68 (17.41)	44.47 (15.65)	46.35 (17.37)	50.36 (17.49)	51.23 (16.18)	48.23 (18.02)	44.60 (15.24)
Female (%)	75%	74%	81%	76%	72%	77%	72%	76%
Mean PHQ-9 ( <i>SD</i> )	18.60 (4.85)	14.88 (4.09)	13.74 (3.00)	15.18 (3.96)	13.22 (2.58)	15.37 (3.88)	13.17 (2.64)	13.67 (3.12)
Moderate depression rating	23%	57%	69%	51%	70%	42%	67%	71%
Moderately severe depression rating	34%	26%	25%	32%	27%	40%	33%	20%
Severe depression rating	42%	18%	6%	18%	3%	18%	0%	9%
Diagnostic	40%	40%	27%	43%	30%	43%	35%	24%
Treatment	37%	32%	31%	44%	34%	42%	22%	27%

641



642 Note: 'Diagnostic' is used to identify participants who self-reported having received a diagnosis of depression. On the other hand,

643 'Treatment' is assigned to participants currently undergoing depression treatment.

644

645



646 Figure 1



647



648

649 Figure 2




650  
651

652 Figure 3



653  
654

655 Figure 4



656